Trials / Completed
CompletedNCT00359944
Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Assessing the Efficacy and Safety of AC-3933 Tablets Twice Daily in Adults With Mild to Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate efficacy and safety of different doses of AC-3933 in patients with mild to moderate Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC-3933 | 5mg twice daily |
| DRUG | AC-3933 | AC-3933, 20 mg twice daily |
| OTHER | Sugar Pill | Sugar Pill twice daily |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2006-08-03
- Last updated
- 2013-07-02
- Results posted
- 2013-07-02
Locations
34 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00359944. Inclusion in this directory is not an endorsement.